Global healthcare and life sciences team represents the international biopharmaceutical company in the agreement.
Sobi (STO: SOBI) and Enable Injections, Inc. have announced a global (ex-US) development agreement and supply agreement across Sobi territories for the enFuse Injector, for the subcutaneous delivery of Aspaveli (pegcetacoplan).
Latham & Watkins LLP advised Sobi in the transaction with a corporate deal team led by San Diego partner Steve Chinowsky, London associate Oliver Mobasser, and San Diego counsel Darryl Steensma.
